Hyperprolactinaemia in early psychosis-not only due to antipsychotics

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 7, 2010, Pages 1342-1344

  Aston, Jacqueline ^a   Rechsteiner, Evelyne ^a   Bull, Nadine ^a   Borgwardt, Stefan ^a   Gschwandtner, Ute ^a   Riecher Rössler, Anita ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antipsychotics; At Risk Mental State; Prolactin; Psychosis; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; RISPERIDONE; TRANQUILIZER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; MALE; MENTAL HEALTH; PROLACTIN BLOOD LEVEL; PSYCHOSIS;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; IMMUNOASSAY; MALE; MENTAL DISORDERS; MENTAL STATUS SCHEDULE; PROLACTIN; SEX FACTORS; YOUNG ADULT;

EID: 77956433136     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.02.019     Document Type: Article

References (28)

1. Biondi M., Picardi A. Psychological stress and neuroendocrine function in humans: the last two decades of research. Psychother Psychosom 1999, 68:114-150.
2. Bushe C., Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol. 2007, 21:768-773.
3. Bushe C., Shaw M., Peveler R.C. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008, 22:46-55.
4. Dickson R.A., Seeman M.V., Corenblum B. Hormonal side effects in women: typical versus atypical antipsychotic treatment. J Clin Psychiatry. 2000, 61(Suppl 3):10-15.
5. Diczfalusy E., Lauritzen C. Psychiatrische und neurologische Erkrankungen. Östrogene beim Menschen 1961, 461-462. Springer, Berlin, Göttingen, Heidelberg. E. Diczfalusy, C. Lauritzen (Eds.).
6. Garner B., Pariante C.M., Wood S.J., Velakoulis D., Phillips L., Soulsby B., et al. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biol Psychiatry 2005, 58:417-423.
7. Grattan D.R., Kokay I.C. Prolactin: a pleiotropic neuroendocrine hormone. J Neuroendocrinol. 2008, 20:752-763.
8. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004, 64:2291-2314.
9. Howard L., Kirkwood G., Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007, 190:129-134.
10. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097.
11. Kinon B.J., Gilmore J.A., Liu H., Halbreich U.M. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003, 28(Suppl 2):55-68.
12. Kraepelin E. Psychiatrie 1909, Barth, Leipzig.
13. Kretschmer E. Körperbau und Charakter. Untersuchungen zum Konstitutionsproblem und zur Lehre von den Temperamenten 1921, Springer, Berlin, Heidelberg, New York.
14. MacMaster F.P., El-Sheikh R., Upadhyaya A.R., Nutche J., Rosenberg D.R., Keshavan M. Effect of antipsychotics on pituitary gland volume in treatment-naive first-episode schizophrenia: a pilot study. Schizophr Res 2007, 92:207-210.
15. Mazure C.M., Quinlan D.M., Bowers M.B. Recent life stressors and biological markers in newly admitted psychotic patients. Biol Psychiatry 1997, 41:865-870.
16. Meltzer H.Y. Biological studies in schizophrenia. Schizophr Bull 1987, 13:77-111.
17. Miller K.K. Management of hyperprolactinemia in patients receiving antipsychotics. CNS Spectr. 2004, 9:28-32.
18. Mondelli V., Dazzan P., Gabilondo A., Tournikioti K., Walshe M., Marshall N., et al. Pituitary volume in unaffected relatives of patients with schizophrenia and bipolar disorder. Psychoneuroendocrinology. 2008, 33:1004-1012.
19. Montejo A.L. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol 2008, 18(Suppl 2):S108-S114.
20. O'Keane V., Meaney A.M. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?. J Clin Psychopharmacol. 2005, 25:26-31.
21. Pariante C.M., Dazzan P., Danese A., Morgan K.D., Brudaglio F., Morgan C., et al. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology. 2005, 30:1923-1931.
22. Riecher-Rössler A. Estrogens and schizophrenia. Estrogen effects in psychiatric disorders 2005, 31-52. Springer, Wien. N. Bergemann, A. Riecher-Rössler (Eds.).
23. Riecher-Rössler A., Häfner H. Schizophrenia and oestrogens-is there an association?. Eur Arch Psychiatry Clin Neurosci 1993, 242:323-328.
24. Riecher-Rössler A., Häfner H., Dütsch-Strobel A., Stumbaum M. Gonadal function and its influence on psychopathology. A comparison of schizophrenic and non-schizophrenic female inpatients. Arch Women's Ment Health 1998, 1:15-26.
25. Riecher-Rössler A., Gschwandtner U., Aston J., Borgwardt S., Drewe M., Fuhr P., et al. The Basel early-detection-of-psychosis (FEPSY)-study-design and preliminary results. Acta Psychiatr Scand 2007, 115:114-125.
26. Riecher-Rössler A., Schmid C., Bleuer S., Birkhäuser M. Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy. Neuropsychiatr. 2009, 23:71-83.
27. Segal M., Avital A., Rojas M., Hausvater N., Sandbank S., Liba D., et al. Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes. Psychiatry Res 2004, 127:227-235.
28. Yung A.R., Phillips L.J., McGorry P.D., McFarlane C.A., Francey S., Harrigan S., et al. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl 1998, 172:14-20.